:format(jpeg):focal(3405x2099:3415x2089)/cloudfront-us-east-1.images.arcpublishing.com/gfrmedia/OWYXYVMNVNGADP6IWYW7QH34WE.jpg)
A small study recently published documents significant recovery of hearing in five of the six children treaties in China. The Children’s Hospital of Philadelphia announced similar improvements Tuesday in an 11-year-old boy treated there. And a few days ago, Chinese researchers published a study showing the same thing in two other children.
At the moment, these experimental therapies are only aimed at a rare disease. But scientists say similar treatments could one day help many more children with other types of genetic deafness.
Worldwide, 34 million children suffer from deafness or hearing loss, and genes are responsible for up to 60% of cases. Hereditary deafness is one of the diseases that scientists are treating with gene therapy, which is already approved to treat diseases such as sickle cell anemia and severe hemophilia.
Children with hereditary deafness often receive a device called a cochlear implant that helps them hear sounds.
“No treatment could reverse the hearing loss… That’s why we always tried to develop a therapy,” says Zheng-Yi Chen of Mass Eye and Ear in Boston, senior author of the study published in the journal Lancet. “We couldn’t be happier and more excited with the results.”
The team captured the patients’ progress on videos. One shows a baby, who previously heard nothing, looking back in response to a doctor’s words six weeks after treatment. Another shows a girl who, 13 weeks after treatment, repeats father, mother, grandmother, sister and “I love you.”
All the children in the experiments suffer from a disease that represents between 2% and 8% of hereditary deafness. It is caused by mutations in a gene responsible for an inner ear protein called otoferlin, which helps hair cells transmit sound to the brain.
The therapy delivers a functional copy of that gene to the inner ear during a one-time surgical procedure. Most children were treated in one ear, although one child – who participated in the two-person study – was treated in both ears.
The study with six children took place at Fudan University in Shanghai, co-directed by Dr. Yilai Shu, who trained in Chen’s laboratory, which collaborated on the research. Funders include Chinese scientific organizations and the Shanghai biotechnology company Refreshgene Therapeutics.
The researchers observed the children for about six months. They don’t know why the treatment didn’t work for one of them. But the other five, who were previously completely deaf, can now hear normal conversation and talk to others. Chen estimates that they now hear at a level between 60% and 70% of normal. The therapy did not cause any major side effects.
The preliminary results of other investigations have been equally positive. New York company Regeneron Pharmaceuticals announced in October that a child under 2 years old, who had undergone a study sponsored with Decibel Therapeutics, showed improvements six weeks after gene therapy.
The Philadelphia hospital – one of several sites in a trial sponsored by an Eli Lilly subsidiary called Akouos – reported that its patient, Spaniard Aissam Dam, heard sounds for the first time after receiving treatment in October. Although the sounds were muffled as if he were wearing foam earplugs, he is now able to hear his father’s voice and the cars on the street, said Dr. John Germiller, who led the research in Philadelphia.
“It’s been a dramatic improvement,” says Germiller. “His hearing has improved from a state of complete and profound deafness, without any sound, to the level of mild to moderate hearing loss, which can be said to be a mild disability. And that is very exciting for us and for everyone.”
Dr. Lawrence Lustig of Columbia University, who is involved in the Regeneron trialsaid that although the children in these studies do not end up with perfect hearing, “even a moderate recovery from hearing loss in these children is quite amazing.”
Still, he added, many questions remain, such as how long the therapies will last and whether hearing will continue to improve in children. Additionally, some people consider gene therapy for deafness ethically problematic.
Teresa Blankmeyer Burke, a philosophy professor and bioethicist at Gallaudet University who is deaf, said in an email that There is no consensus on the need for gene therapy for deafness. He also noted that deafness does not cause serious or fatal diseases such as sickle cell anemia. He said that It is important to involve members of the deaf community in the debate about prioritizing gene therapy, “especially since this is perceived by many as a possible existential threat to the flourishing of deaf communities who communicate with sign language.”
Meanwhile, the researchers said their work continues. “This is real proof that gene therapy works,” Chen said. “That opens the doors to investigation.”
